LAURUSLABS · NSE
Laurus Labs Limited
₹1,954
+0.30% (+₹5.9)
Prev. close
₹1,948.1
Volume
26,55,873
Delivery %
69.7%
As of
18 Sept 2026
Price history
Chandan Taparia · Motilal Oswal Financial Services Ltd · 31 Aug 2026
“Bullish on Laurus Labs, recommending a buy at CMP Rs 1,938 with a target of Rs 2,050 and a stop loss of Rs 1,880. The stock is in a strong uptrend, trading at all-time highs, outperforming the broader market, and has formed higher highs while respecting its 20 DEMA.”
Entry ₹1,938Target ₹2,050 (+5.8%)Stop ₹1,880 (-3.0%)R:R 1.9:1Stopped out · 31 Aug 2026
Analyst sentiment
Analysts lean bullish
2 analyst stances · last 90 days · one per analyst
Trackable
2 · 2 bull / 0 neutral / 0 bear
Long-Horizon
none in window
Commentary
none in window
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions | |||
|---|---|---|---|---|---|---|---|
| “Bullish on Laurus Labs, recommending a buy with a target price of ₹2,050 and a stop loss of ₹1,890. The stock is in an o…” | Chandan TapariaMotilal Oswal Financial Services Ltd | Laurus Labs | PENDING | ||||
| “Bullish on Laurus Labs, recommending a buy at ₹1867 with a target of ₹1900 and a stop loss at ₹1840.” | Vaishali ParekhPrabhudas Lilladher | Laurus Labs | PENDING | ||||
| “Bullish on Laurus Labs, recommending a buy at CMP Rs 1,938 with a target of Rs 2,050 and a stop loss of Rs 1,880. The st…” | Chandan TapariaMotilal Oswal Financial Services Ltd | Laurus Labs | PENDING | ||||
“Bullish on Laurus Labs, recommending a buy at CMP Rs 1,938 with a target of Rs 2,050 and a stop loss of Rs 1,880. The stock is in a strong uptrend, trading at all-time highs, outperforming the broader market, and has formed higher highs while respecting its 20 DEMA.” This call hasn't reached its evaluation window yet — the verdict will appear here once it's graded. | |||||||
| “Bullish on Laurus Labs, recommending a buy with a target price of ₹2,050 and a stop loss of ₹1,870. The stock has shown …” | Chandan TapariaMotilal Oswal Financial Services Ltd | Laurus Labs | PENDING | ||||
Fundamentals
About Laurus Labs Limited
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology. It also develops and manufactures animal-origin-free recombinant proteins and cell-culture media supplements and research and development services, including drug substance development, drug product development, and biologics development. In addition, the company offers non-human ingredients; rare disease therapeutics; and finished dosages. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Satyanarayana Chava M.Sc., Ph.D.
Headquarters
Hyderabad
Employees
7,059
Website
lauruslabs.comExchange
View on NSE ↗Key stats
Market cap
₹1.05 L Cr
P/E ratio (TTM)
96.4
Dividend yield
0.13%
EPS (TTM)
₹20.20
Beta (1Y · daily vs NIFTY 50)
0.80
Beta (5Y · monthly vs NIFTY 50)
1.00
Shares float
36.34 Cr
EPS · quarter ended Jun 2026
₹6.80
Upcoming earnings
22 Oct 2026
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.4% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹4,813.51 Cr | ₹4,935.57 Cr | ₹6,040.55 Cr | ₹5,040.83 Cr | ₹5,553.96 Cr | ₹6,812.90 Cr | |
| EBITDA | ₹1,574.34 Cr | ₹1,437.73 Cr | ₹1,598.19 Cr | ₹803.84 Cr | ₹1,130.38 Cr | ₹1,832.66 Cr |
| ₹983.82 Cr | ₹827.52 Cr | ₹790.11 Cr | ₹160.55 Cr | ₹358.32 Cr | ₹888.79 Cr | |
| Diluted EPS | ₹18.28 | ₹15.35 | ₹14.64 | ₹2.97 | ₹6.64 | ₹16.45 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹5,751.00 Cr | ₹6,968.00 Cr | ₹7,660.00 Cr | ₹8,387.00 Cr | ₹9,336.00 Cr | ₹10,511.00 Cr | |
| — | — | ₹2,015.09 Cr | ₹2,577.40 Cr | ₹2,763.73 Cr | ₹2,518.48 Cr | |
| Stockholders' equity | ₹2,597.00 Cr | ₹3,351.00 Cr | ₹4,038.00 Cr | ₹4,111.00 Cr | ₹4,473.00 Cr | ₹5,300.00 Cr |
Current assets, Inventory, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹733.00 Cr | ₹911.00 Cr | ₹994.00 Cr | ₹666.00 Cr | ₹602.00 Cr | ₹1,624.00 Cr | |
| Investing cash flow | ₹-940.99 Cr | ₹-914.34 Cr | ₹-996.06 Cr | ₹-822.42 Cr | ₹-681.72 Cr | ₹-1,088.66 Cr |
| ₹255.00 Cr | ₹30.00 Cr | ₹-27.00 Cr | ₹250.00 Cr | ₹39.00 Cr | ₹-525.00 Cr | |
| Capital expenditure | ₹-689.00 Cr | ₹-877.00 Cr | ₹-990.00 Cr | ₹-678.00 Cr | ₹-641.00 Cr | ₹-1,070.00 Cr |
| End cash position | ₹48.46 Cr | ₹75.35 Cr | ₹45.67 Cr | ₹138.94 Cr | ₹99.54 Cr | ₹112.66 Cr |
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21–Sep 22(4Q) | Dec 22–Sep 23(4Q) | Dec 23–Mar 24(2Q) | Jun 24–Sep 24(2Q) | Dec 24–Mar 25(2Q) | Jun 25–Sep 25(2Q) | Dec 25–Mar 26(2Q) | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 27.30% | 27.27% | 27.20% | 27.19% | 27.18% | 27.62% | 27.59% | 27.49% | 27.47% |
| Public | 72.70% | 72.73% | 72.80% | 72.81% | 72.82% | 72.38% | 72.41% | 72.51% | 72.53% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Aurobindo Pharma Limited | ₹97,238.87 Cr | ₹1,734 | 26.4 | 2.57 | 9.2% | 0.21 | +6.4% | +53.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Show all 13
Concall transcripts
Show all 13
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
45 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Is Laurus (LAURUSLABS.NS) Still a Buy After +2.24% Rally? 2026-09-17 - VOLD Alert
siam.in · 1 day ago